Exscientia plc
exscientia.aiNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2023 20-F, filed Mar 21, 2024. Its latest SEC filing is a 15-12G from Dec 2, 2024.
20-F for FY2023, filed Mar 21, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Designs drug candidates and discovery programs with AI and laboratory experiments for pharmaceutical partners, while advancing its own medicines, mainly in oncology.
20-F for FY2023, filed Mar 21, 2024We are a drug design company using artificial intelligence, or AI, and other technologies to efficiently design and develop differentiated…View ↗
We believe many drug candidates fail due to predictable drug design issues. For more than a decade, we have been utilising AI to overcome…View ↗
Focused pipeline. Our platform allows us to rapidly discover new molecules. While the technology that drives our precision design approach…View ↗
Who Were Their Customers?
Pharmaceutical partners work directly with Exscientia through drug-discovery and licensing collaborations, including Bristol Myers Squibb, Sanofi and Merck KGaA.
20-F for FY2023, filed Mar 21, 2024Licensing fees: We receive licensing fees from partnered programmes where we develop intellectual property on behalf of a collaboration…View ↗
We designed a PKC-theta inhibitor for Bristol Myers Squibb that they then in-licensed and are currently testing in Phase 1 clinical trials.…View ↗
On September 19, 2023 the Group and the Healthcare Business of Merck KGaA, Darmstadt, Germany (“Merck KGaA, Darmstadt, Germany”), entered…View ↗
Did Revenues Turn Into Profits?
No. It lost GBP 146M in .
20-F for FY2023, filed Mar 21, 2024
Who Did They Compete With?
Competes with Relay Therapeutics, AbCellera, Schrodinger, Recursion Pharmaceuticals, PathAI, Insitro, Valo Health, Cellarity, XtalPi, BenevolentAI, Absci, and Atomwise
20-F for FY2023, filed Mar 21, 2024We are aware of several companies using various technologies, including AI and other sophisticated computational tools, to accelerate drug…View ↗
Loading...
